Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

A widely used hospital antibiotic has been linked to a small rise in deaths

Qurexa Editorial Team15 September 20266 min read 0 0
A widely used hospital antibiotic has been linked to a small rise in deaths

What happened

Researchers have taken a fresh look at a question doctors have argued about for years: is the antibiotic cefepime as safe as the alternatives? Cefepime is a strong antibiotic given through a drip in hospital. It is used for serious infections, including in people whose immune systems are weakened by cancer treatment. It belongs to a family of medicines called beta-lactams, which also includes penicillins. A team led by Zahra N. Sohani, from the Division of Infectious Diseases and Medical Microbiology in Montreal, Canada, pulled together the results of 110 randomised clinical trials. Between them, those trials included 22,608 patients. Just over 11,700 were given cefepime. Nearly 10,900 were given a different beta-lactam antibiotic to compare against. The findings were published in JAMA Network Open and reported in the medical press on 14 September 2026. In the cefepime group, 778 people died, or 6.6 per cent. In the comparison groups, 674 people died, or 6.2 per cent. Using a statistical method called Bayesian analysis, the researchers calculated a 94.4 per cent probability that cefepime really was linked to a higher risk of death, rather than the difference being down to chance. That is a small gap in absolute terms. But cefepime is given to very large numbers of seriously ill people, so a small gap can still matter.

Why this matters

This is not a new worry. Around 16 years ago the United States Food and Drug Administration looked into the same question and concluded that cefepime did not raise the risk of death. That finding helped settle the argument, and the medicine has been used widely ever since. What has changed is the amount of evidence. There are far more trials now than there were then, and the methods for combining them have improved. Pooling 110 trials gives a much clearer picture than any single study could. It also matters because cefepime is often the antibiotic reached for when someone is very unwell and doctors do not yet know exactly which bug is causing the problem. In those moments, the choice between one broad antibiotic and another is made quickly. Evidence that helps doctors make that choice well is valuable. It is worth saying plainly what this does not mean. Nobody is saying cefepime should be withdrawn. Nobody is saying patients who have had it should be alarmed. Antibiotics save lives every day, and the risk of leaving a serious infection untreated is far greater than the difference this study describes.

What the evidence actually says

A few details are worth keeping in mind. First, this is a meta-analysis. It combines trials that were run by different teams, in different countries, on different groups of patients. That is a strength, because it gives large numbers. It is also a weakness, because the trials were not designed to be added together, and the people in them were not all alike. Second, the difference is small: 6.6 per cent against 6.2 per cent. Put another way, the great majority of people in both groups survived, and most of the difference in outcome between patients will have been driven by how ill they were in the first place, not by which antibiotic they received. Third, the researchers offer a possible explanation, and it is an interesting one. Cefepime has what doctors call a narrow therapeutic window. That means the gap between too little and too much is smaller than with some other antibiotics. Too little may not clear the infection. Too much can affect the brain and cause confusion, which is a known side effect of cefepime, especially in people whose kidneys are not working well. The authors suggest the mortality signal may come from both ends, from underdosing and from overdosing. If that is right, the answer is not necessarily to stop using cefepime. It may be to dose it more carefully, particularly in people with kidney problems, and to monitor more closely.

Practical advice

Most people reading this will never be prescribed cefepime. It is a hospital medicine given by drip, not something collected from a pharmacy. If you or a relative is in hospital on antibiotics, the useful things to do are simple. Make sure the team knows about kidney problems. Kidney function affects how quickly the body clears many antibiotics, cefepime included. If you have chronic kidney disease, say so, and make sure it is on the record. Bring an up-to-date list of all medicines, including anything bought over the counter and any herbal remedies. It sounds small. It prevents a surprising number of problems. Speak up about new confusion. If someone on antibiotics in hospital becomes unusually muddled, drowsy or agitated, tell a nurse or doctor rather than assuming it is just the illness or being in a strange place. With cefepime in particular, confusion can be a sign that the dose needs reviewing. Do not stop a course of antibiotics on your own. If you have concerns about a medicine you are on, raise them with the team looking after you. Stopping early can allow an infection to come back stronger. And for antibiotics generally: take them exactly as prescribed, finish the course unless a healthcare professional tells you otherwise, and never save leftovers for next time or share them with someone else.

What to know

A large analysis of 110 clinical trials, covering 22,608 patients, has linked the hospital antibiotic cefepime to a slightly higher risk of death than similar antibiotics: 6.6 per cent compared with 6.2 per cent. The researchers calculated a 94.4 per cent probability that the difference is real rather than chance. The likely explanation may be dosing. Cefepime has a narrow margin between too little and too much, and getting it wrong in either direction can cause harm. This is a question for hospital doctors and pharmacists, not something patients need to act on themselves. Antibiotics remain one of the most important tools in medicine, and an untreated serious infection is far more dangerous than this difference. Sources: JAMA Network Open, 'Cefepime and mortality compared with other beta-lactam antibiotics: a systematic review and Bayesian meta-analysis', Sohani et al., September 2026, https://jamanetwork.com/journals/jamanetworkopen. Medical Xpress, 'Common antibiotic linked to possible higher death risk', 14 September 2026, https://medicalxpress.com/news/2026-09-common-antibiotic-linked-higher-death.html. Medical Dialogues, 'Cefepime Linked to Higher Mortality Risk Than Other Beta-Lactams: Study', September 2026, https://medicaldialogues.in/medicine/news/cefepime-linked-to-higher-mortality-risk-than-other-beta-lactams-study-179153. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never stop or change a prescribed antibiotic without speaking to the team treating you.

#antibiotics#hospital care#patient safety#research#infection#medicines

Related articles